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Mesangial re-modeling and mesangial cell (MC) migration
are features of several glomerular diseases including
mesangiocapillary glomerulonephritis. In vitro investigations
have recently identified ADAM-15, a multidomain
adamalysin, as central to the migration of MC. The current
study used array technology to investigate the expression of
other genes in migrating cells and identified pleiotrophin
(PTN), platelet-derived growth factor alpha polypeptide
chain, colony stimulating factor, and four members of the
tumor necrosis factor-a superfamily as major genes that were
upregulated. Transcriptional induction of PTN was confirmed
by reverse transcription-polymerase chain reaction and
Northern blotting and induction of the protein by Western
blotting and immunohistochemical localization. PTN was
observed associated with mesangial ‘hillocks’ in confluent MC
cultures. In contrast, in models of migration, migrating cells
had the highest expression of cell-associated PTN. PTN
protein was less evident, however, in the conditioned
medium of MCs. Treatment of MC with heparanase removed
PTN from the cells suggesting that its localization was owing
to an association with heparan sulfates on the cell surface or
in the extracellular matrix. This is the first description of the
expression of PTN by human MCs and the data suggest that
it is rapidly induced in cells that are triggered to migrate. The
result of this induction is currently under investigation.
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The mesangium, comprising mesangial cells (MCs) and the
extracellular matrix that they synthesize, the mesangial
matrix, forms the structural core of the glomerulus. In
addition to this architectural function, however, the mesan-
gial matrix has a central role in homeostasis and the normal
functioning of the glomerulus. The major components of this
matrix include collagen type IV, laminin, fibronectin, and a
number of different heparan sulfate, chondroitin sulfate, and
dermatan sulfate proteoglycans. In the normal kidney these
components are maintained at constant levels owing to the
balance between the synthesis and deposition of extracellular
matrix components and their proteolytic breakdown. In a
number of renal diseases this equilibrium is shifted and, as a
result, the normal composition of the mesangial matrix is
altered leading to glomerulosclerosis and loss of renal
function. Furthermore, in a number of renal diseases, MCs
become motile and migrate through the remodeled matrix
into the pericapillary space.1 This migration is mediated
through interactions with a range of extracellular matrix
molecules such as thrombospondin,2 fibronectin, 3 and
heparan sulfate glycosaminoglycans.4
Our recent studies into the mechanisms involved in MC
motility have revealed that ADAM-15, a member of the
adamalysin family of cell surface molecules, is strongly
involved in MC migration. The potential involvement of
soluble mediators as factors synthesized during MC migra-
tion, however, has not been addressed. In a recent report,
Henger et al.5 used gene expression fingerprinting technology
to examine differential gene expression profiles in the kidneys
of patients with progressive fibrosis. Of nine genes identified
as having a role in progression, seven were also associated
with inflammation. The two genes associated solely with
fibrosis were the b4 integrin chain and the soluble mediator
pleiotrophin (PTN).
PTN is a member of the midkine family of molecules and
has over 50% homology with midkine. Both are retinoic
acid-inducible molecules, although, unlike midkine, PTN has
been shown to be induced by platelet-derived growth factor
alpha polypeptide (PDGFA), and may be a downstream
effector of this cytokine. PTN is a 136 amino acid, 15.3 kDa
protein, and is also known as heparin binding growth-
associated molecule, embryonic differentiation factor, and
heparin affinity regulatory peptide. It is very highly conserved
across species, with over 98% homology between human,
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mouse, rat, and bovine.6 PTN is involved in a range of
biological processes; it has important functions in renal
development7,8 and induces proliferation of human blood
peripheral mononuclear cells.9 Elevated levels have also
recently been shown in osteoarthritis.10 As a proto-oncogene,
it has been implicated in tumor angiogenesis, cell differentia-
tion, and the development of spleen and lung cancers.11,12
Furthermore serum PTN levels have been suggested as a
marker for these diseases.
As PTN is upregulated in renal disease, the current study
was undertaken to establish whether PTN was synthesized by
MC and whether its expression was increased in MC during
migration.
RESULTS
Wounded monolayers of human MCs upregulate PTN
mRNA expression
Confluent MC were multi-scratched and messenger RNA
(mRNA) was extracted. Complementary DNA was prepared
using the cytokine-specific primers supplied with the
common cytokine gene ‘Super Array’ kit. Scratched cultures
were compared to corresponding unscratched control
cultures. The expression of several cytokines was markedly
upregulated following scratching, including the pluripotent
cytokine PTN and the tumor necrosis factor (TNF) super-
family member, TNF (ligand) superfamily member (Figure 1).
The arrays were subjected to densitometric analysis and
the ratio of each mRNA spot was normalized to that of the
housekeeping genes on each respective blot before compar-
ison between blots. The results are presented in a bar chart
(Figure 2). This analysis confirmed the relative increase in the
mRNA coding for PTN and also demonstrated upregulation
of other genes, such as colony stimulating factor 1, and
several members of the TNF super family. There were also
genes, however, which showed reduced activity, including
transforming growth factor beta 2. These results were
confirmed by stripping the blots and (following confirmation
of the total removal of probes) repeating the experiment
using mRNA from a second MC culture with and without
multi-scratch wounding as before (data not shown).
In order to confirm the findings from the gene array
experiments, primers were designed from the sequences of
PTN deposited in the GenBank database. There were several
distinct sequences deposited that are reported to code for
PTN but all had an overlapping consensus sequence. Primers
were designed within this consensus sequence and, using
reverse transcription-polymerase chain reaction (RT-PCR),
these confirmed the presence of the PTN mRNA in MCs and
its time-dependent induction, which peaked at 3 h after cells
were subjected to multi-scratch wounding. The levels of
mRNA were found to be somewhat variable between MC
cultures, but the PTN:actin ratio was consistently found to be
increased in the migrating cells relative to the non-migrating
cells (Figure 3a and b). In addition, Northern blotting was
carried out using RNA prepared from scratched and control
MC cultures and these investigations confirmed both the
presence of PTN mRNA and its induction in wounded cell
monolayers (Figure 3c).
Wounded monolayers of human MCs upregulate PTN protein
expression
Western blotting of the MC culture medium showed the
presence of PTN, which was detected as a single band of
18 kDa. This band, however, was variably present and in
some experiments PTN could not be detected at all in the
culture medium (not shown).
Immunostaining MC with anti-PTN antibodies demon-
strated punctate cell-surface staining for PTN. There was a
marked increase in staining associated with ‘hillocks’ of MCs
(Figure 4b). Furthermore, cell surface staining for PTN
(Figure 4c) was reduced following heparitinase treatment
(Figure 4d) confirming that PTN binding was mediated
through an interaction with cell- and matrix-associated
heparan sulfate.
In addition, MCs were shown to stain positive for PTN
when analyzed by fluorescence-activated sell sorter (FACS).
The amount of staining was increased when the cells were
migrating following multi-scratch wounding. Figure 5 shows
the shift of PTN staining at 72 h compared to non-migrating
cells. This induction of cell-associated PTN was seen as early
at 4 h and was present for at least 72 h. There was a time-
dependent induction of cell-associated PTN beginning at 4 h
(25% of cells in region M2 compared to 12% of control cells)
following scratch wounding. This expression reached a
plateau by 24 h and by 72 h 28% of the cells were in region
M2 (Figure 5). Together these findings suggest that there is a
mechanism for maintaining PTN in association with the cell
and that there may also be a mechanism for triggering its
release.
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Figure 1 | A representative expression array of mRNA from
control and multi-scratched MC cultures. mRNA was isolated
after72 h incubation from (a) untreated cells or (b) following
multi-scratch wounding. mRNA was labeled and hybridized to a
common cytokine array as described. Two of the most strongly
induced cytokines (PTN and tumor necrosis factor (ligand)
superfamily member 4) are shown together with the three control,
housekeeping genes (ribosomal protein L, glyceraldehyde-2-
phosphate dehydrogenase, and actin B).
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Association between PTN and PDGFA chain expression
Platelet-derived growth factor (PDGF) is a strong mitogen
and inducer of migration in MCs. Following multi-scratch
wounding, PDGFA mRNA was induced in a time-dependent
manner (Figure 6). To investigate the possibility that there
was a causal link between the upregulation of PTN and that
of PDGFA, cells were treated with either heparitinase or the
PDGF receptor signaling blocker, AG1296, to inhibit PTN- or
PDGF-dependent responses, respectively. Semiquantitative
RT-PCR was then carried out to examine the subsequent
effect on PDGF or PTN mRNA levels, respectively. Blocking
MC responses to PDGF resulted in significant inhibition of
the induction of PTN mRNA (Table 1A) at both 1 h (76.9%
inhibition) and 3 h (59.8% inhibition), suggesting that PDGF
may be a major factor involved in the stimulation of PTN
release in MC. Importantly, however, heparitinase treatment
significantly inhibited the induction of PDGFA mRNA by
81.8% at 1 h and 78.7% at 3 h (Table 1B), suggesting an
amplification loop involving the two cytokines.
DISCUSSION
We have recently begun in vitro investigations into the
mechanisms involved in initiating and controlling MC
migration and in the current study we have addressed the
possibility that there are soluble mediators released when MC
are induced to migrate. This work is the first report that PTN
is produced by MCs in vitro, and furthermore that PTN was
induced in migrating cells as shown by cytokine array. In this
migration assay, following the initial period of migration the
cells will begin to proliferate as they expand – as in the typical
reaction of cells during the wound healing process. PTN
binds to extracellular matrix and with high affinity to
heparin.13 Thus treatment of cells with heparitinase removes
bound PTN and in our study this also reduced the induction
of PDGFA chain mRNA, suggesting that PTN (but we cannot
rule out other additional heparin-binding growth factors)
directly controls synthesis of PDGF by MC. PTN, colony
stimulating factor, and members of the TNF superfamily
were all increased with PDGFA chain by the induction of
migration. PDGF has previously been implicated in the
production of PTN,14 and so the presence of the mRNA for
this molecule in our arrays may indicate the specific
stimulation of a small group of cytokines that interact and
are possibly co-regulated in migrating cells. This is further
supported by our results using blockade of the PDGF-
receptor signaling cascade by AG1296. This prevented the
induction of PTN mRNA, confirming an association in
controlling MC function and a potentially important
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Figure 2 | Bar chart showing relative amounts of cytokine mRNA in migrating compared to non-migrating MCs. Cytokines showing the
greatest induction or inhibition following scratching are labeled. Results are representative of two independent experiments.
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interdependence of these two cytokines. PTN has recently
been shown to also bind specifically to a chondroitin sulfate
proteoglycan, with a downstream signaling system which
includes extracellular signal-regulated kinase and phospha-
tidylinositol 3 kinase.15 In our studies, however, we found no
effect of digesting cell surface chondroitin sulfate chains with
chondroitinase ABC (not shown).
There are several reports of the PTN molecule being
upregulated in cancers. Initial reports described the upregu-
lation this cytokine in breast16 and spleen cancer,11 although
several other types of cancer are now believed to show an
increased production of this molecule, for example, pancrea-
tic cancer,17 and lung cancer12 and testicular cancer.18
Pleitrophin has also been implicated in both rheumatoid
arthritis19 and osteo-arthritis.10
Although considered primarily as a mitogen, there has
been one report describing PTN involvement in wound
healing in rat dermal cells.13 This is one of the first reports
demonstrating the involvement of PTN in the migration of
cells in vitro, and is indicative of the multi-functional but
related role possessed by this growth factor. There has,
however, been a recent report describing the involvement of
PTN in osteoprogenitor cell migration.20 In addition, PTN
and its receptor tyrosine phosphatase-zeta have been
implicated in regulating glioblastoma cell motility both in
the soluble phase21 and when PTN was immobilized.22 There
is also, however, a contrasting report where PTN was found
to have no effect on either glioblastoma or endothelial cell
migration.23
All of the reports referred to above associate the molecule
with a role in angiogenesis or mitogenesis or in the migration
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Figure 3 | Time course of induction of PTN. (a) Multi-scratch
wounds were inflicted on human MC and RNA was extracted at the
indicated times. The RNA was amplified by RT-PCR and products
separated in 2% agarose gels with actin as the housekeeping gene.
(b) Results shown in are the means 7s.d. of the densitometric
analyses from seven independent experiments. (c) In addition, the
mRNA from 3 h incubations was compared by Northern blotting to
that prepared from control non-migrating cells by hybridizing with a
PTN-specific probe. Equal loading was confirmed by stripping the
blot and re-probing for glyceraldehyde-2-phosphate dehydrogenase
(*Po0.05 compared to 0 h).
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Figure 4 | PTN is expressed on the surface of MC.
Immunohistochemical staining of human MCs for the PTN protein
demonstrated increased amounts associated with MC hillocks.
Mesangial cells were grown to confluence and allowed to produce
the distinctive protein rich ‘hillocks’. Cells and hillocks were viewed
under brightfield (a) or stained with anti-PTN and visualized with
fluorescein isothiocyanate conjugated second antibody (b–d). In
(c and d), cell surface staining for PTN is shown reduced following
heparitinase treatment. Mesangial cells were grown to confluence
as before and incubated with either PBS (no treatment) as control
(i) or heparitinase (ii) following which immunohistochemistry was
performed as before in order to visualize the presence of PTN
on the cells.
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Figure 5 | FACS analysis of PTN expression by human MCs. Cells
were subjected to multi-scratch wounding or left untreated and
prepared for FACS analysis of PTN expression as described in
Materials and Methods. Results show the increased expression of PTN
at 72 h and are representative of three independent experiments.
Solid peak shows the PTN expression in non-migrating cells. Gray
line represents the shift in PTN expression in migrating cells.
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of cells, often in cancer or inflammation. These results would
tie in with our finding of the involvement of the cytokine in
our in vitro model of wound healing, and provide a new
possible target for the modulation of healing wounds in vivo.
In conclusion, PTN mRNA was detected by using cytokine
arrays and was shown to be induced when MC were
stimulated to migrate. We have confirmed that these cells
in vitro both express the PTN mRNA and produce the PTN
protein. Having defined a role for PTN in vitro, studies in
vivo will now be possible to define its involvement as a
paracrine or autocrine factor. Given the potency of this
molecule it is likely that its generation in vivo would have a
marked effect on glomerular function.
MATERIALS AND METHODS
All general reagents were from Sigma-Aldrich, Poole, Dorset, UK),
unless stated otherwise. All tissue culture reagents were obtained
from BRL Life Technologies (Gibco BRL), Gaithersburg, MD, USA.
Electrophoresis reagents were purchased from BioRad Laboratories
Ltd, (Hemel Hempstead, Herts, UK).
Cell culture and identification
MC were cultured from human glomeruli obtained by the serial
sieving of the kidney. MCs were maintained in Rosewell Park
Memorial Institute media-1640 containing 20% v/v fetal calf serum.
Before experimental procedures MC were growth arrested for 48 h
by culture in medium containing 0.2% (w/v) lactalbumin hydro-
lysate (Difco Laboratories, Detroit, MI, USA) in the absence of
serum.24 The cells were confirmed to be MCs by morphology and
the use of immunohistochemistry as described.25 Cells showed
positive staining for intracellular myosin fibrils, and were negative
for factor VIII and cytokeratin. Three separate cell lines were used
for the RT-PCR and Western blot analysis, two of which were used
in the cytokine array study.
Confluent MC were multi-scratch wounded in order to induce a
high percentage of migrating cells in the cultures.26 RNA was
collected from both scratched and control dishes using RNA Isolator
(Genosys Ltd, Cambridge, UK) according to the manufacturers
instructions.
Treatment with heparatinase
Semiconfluent cell layers grown in 8 well chamber slides were
scratch wounded and incubated for a further 24 h. To remove cell-
surface heparan sulfate glycosaminoglycan chains they were then
washed with phosphate-buffered saline (PBS) and incubated with
0.3 mU/ml each of heparatinase I, II, and III in the absence of serum
for 30 min. The cultures were then fixed and stained for PTN as
detailed below.
Common cytokine super array analysis
Complementary DNA was prepared using the cytokine-specific
primers supplied with the common cytokine gene ‘Super Array’
kit.27 The probes were prepared using the ‘Strip Easy’ protocol and
materials28 in order to allow the membranes to be used for three
separate hybridizations. Radiolabeled complementary DNA tran-
scripts were hybridized to the two identical ‘Super Array’27
membranes pre-spotted with sequences specific to each of a variety
of common cytokines. Cytokine spot densitometry was quantified
by use of the ‘Chemi Doc Gel Quantification System,’ with ‘Quantity
One’ Software (BioRad Labs), and data analyses performed using the
‘super array’ GEArray Analyzer software. The membranes were then
stripped using the ‘Strip Easy’ manufacturers protocol and the
removal of the probes was confirmed. An unconnected experiment
was then performed in order to ensure a different pattern of results
was obtained using the membranes, which were then re-stripped
and the multi-scratch experiment repeated as before using a
different MC line.
RT-PCR
Confluent 35 mm dishes of MCs were growth arrested and multi
scratches introduced as described. Total RNA was extracted using
RNA Isolator at various time points following the initiation on the
scratch and complementary DNA was prepared by the reverse
transcription of 1 mg of RNA using random primers and the
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Figure 6 | PDGFA chain is induced in scratch-wounded MC. RT-PCR
for PDGFA demonstrated a time-dependent increase in the PDGFA
chain mRNA in migrating human MCs. Multi-scratch wounds were
inflicted on human MC and was RNA extracted at the indicated times.
PDGF mRNA was then amplified by RT-PCR and products separated in
2% agarose gels with actin as housekeeping gene. (a) The gel is
representative of five separate experiments and (b) the mean
densitometry values (7s.d.) of PDGFA corrected for the density
of the corresponding actin values are shown.
Table 1 | (A) Semiquantitative RT-PCR for PTN in AG 1296-
treated cellsa and (B) semiquantitative RT-PCR for PDGFA
chain in heparitinase-treated cellsa
(A)
Time from scratch induction 1 h 3 h
Without treatment 1.4970.7 1.1370.21
With treatment 0.3570.17 0.6070.25
(B)
Time from scratch induction 1 h 3 h
Without treatment 4.9570.9 3.7570.8
With treatment 0.9070.18 0.8070.20
PDGFA, platelet-derived growth factor alpha polypeptide; PTN, pleiotrophin;
RT-PCR, reverse transcription-polymerase chain reaction.
aMC cultures were multi-scratched and RNA extracted as described in the Materials
and Methods section.
The densitometry ratio of either PTN (A) or PDGFA (B) to that of the housekeeping
gene (b-actin) were calculated and the results are expressed as the mean of
these7s.d. of three independent experiments.
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equivalent of 0.05 mg was amplified by PCR using the following
primers specific for PTN and actin and PDGF A. (Genosys Ltd,
Cambridge, UK).
PTN primers:
50-CCTTCTTGGCATTCATTTTCAYACTGG-30
50-GAGGTTTGGGCTTGGTCAGTTTGC-30
Cycle number: 35
Actin primers:
50-GGAGCAATGATCTTGATCTT-30
50-CCTTCCTGGGCATGGAGTCCT-30
Cycle number: 30
PDGF A primers:
50-AATTTCGCCGCCACAGGAGA-30
50-ACGGGGGCCAGATCAGGAAG-30
Cycle number: 35
Northern Blot analysis
Total RNA (up to 10 mg) was run on a denaturing agarose gel
and transferred by vacuum blotting onto a Hybond nylon
membrane (Amersham, UK). mRNA for PTN was detected
by hybridization with a 32P-labeled probe prepared from PCR
product and detected as described previously.29
Western blotting
MC-conditioned medium was collected, and an equivalent
volume, corrected for cell number as determined by the
reduction of Alamar Blue,30 was applied to 7.5% sodium
dodecyl sulfate-polymerase chain reaction gels and separated
under reducing conditions. Following electrophoretic trans-
fer to nitrocellulose and blocking in 5% skimmed milk in
PBS containing 0.5% Tween 20, the blots were incubated with
0.1 mg/ml anti-PTN antibody (R&D systems, Abingdon,
Oxon, UK) in PBS, 0.1% Tween 20, 1% bovine serum
albumin overnight. The blots were then incubated with
horseradish peroxidase-conjugated anti-Goat IgG for 2 h, and
antibody binding was visualized by enhanced chemilumines-
cence (Amersham Pharmacia Biotech UK Ltd, Little
Chalfont, UK). Detected bands were quantified by use of
the ‘Chemi Doc Gel Quantification System,’ using ‘Quantity
One’ Software (BioRad Labs).
FACS Analysis of cell-associated PTN
Following multi-scratch wounding for the appropriate times,
cells were removed by mild trypsin/ethylenediaminetetra-
acetic acid treatment. The trypsin was neutralized by the
addition of 10% fetal calf serum and the cells pelleted by
centrifugation (1500 r.p.m. 7 min). They were then fixed and
permeabilized in 100 ml of Cytofix/Cytoperm for 20 min and
washed  2 in Perm/wash solution (BD Biosciences 10 975
Torreyana Road San Diego, CA, USA), according the to the
manufacturers protocol. Cells were incubated with goat anti-
PTN antibody diluted to 1/500 at 41C for 30 min. After
washing  2 in Perm/wash solution cells were incubated with
anti-goat fluorescein isothiocyanate (1/400) for 30 min at
41C, washed and finally resuspended in 250 ml of Perm/wash
solution and 10 000 cells were analyzed per sample by flow
cytometry (FACSCalibur, Becton Dickinson, Oxford, UK).
Immunohistochemistry
MCs were grown to confluence in eight-well chamber slides,
and half the cells were removed by scratching. The cells were
incubated for a further 24 h at which point the cells were
fixed in ice cold acetone:methanol (50:50) for 5 min, washed,
and incubated with anti-PTN antibody 1/200 in PBS bovine
serum albumin (1%) (Santa Cruz Biotechnology Inc., Santa
Cruz, CA, USA, sc-1394: Autogen Bioclear, Holly Ditch
Farm, Mile Elm, Calne, Wiltshire SN11 0PY) for 3 h at room
temperature. The cells were then incubated for a further 3 h
in the presence of anti-goat fluorescein isothiocyanate
conjugated secondary antibody (Sigma-Aldrich, Poole,
Dorset, UK) diluted 1/80, washed, mounted in Vectashield
(Vector Laboratories Burlingame, CA, USA) and visualized
using a fluorescence microscope (Leitz Dialux 20 EB).
Inhibition of PTN and PDGFA transcription
To investigate whether there was a causal relationship
between the upregulation of PTN and PDGFA, cells were
incubated with AG1296, an inhibitor of PDGFA signaling, or
heparitinase, to disrupt presentation to the PTN receptor.
Semi confluent cell layers grown in eight-well chamber slides,
or 24-well plates were washed with PBS and then further
incubated in the presence of 3.8 mM AG1296 for up to 6 h, and
RNA collected for RT-PCR for PTN or for 24 h at which
point the cells were washed fixed and stained as above.
For inhibition of PTN effects, semiconfluent cell layers
grown in 24 well plates were washed with PBS and then
further incubated in the presence of heparatinase I, II, and
III (0.3 mU/ml) for up to 6 h. The RNA was collected for
RT-PCR for PDGFA as detailed above.
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